Novartis Investigative Site

Beelitz-Heilstätten 14547

0 studies enrolling now · 4 studies all time

What they study most

Anti-Dyskinesia Agents, Dyskinesias, Movement Disorders, Parkinson Disease, Parkinson's Disease Dementia, Parkinsonian Disorders

Studies at this site

• Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias — Completed
• Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias — Completed
• Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias — Completed
• Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD) — Completed